Adicet Bio (ACET) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
17 Jun, 2026Opening remarks and agenda
The meeting was called to order by the CEO, with the CFO appointed as Secretary to record minutes.
Stockholders were welcomed, and the meeting was confirmed to be held in accordance with bylaws and Delaware law.
Directors, executive team, audit firm, and outside counsel were introduced.
Rules of conduct and voting eligibility were explained, with instructions for submitting questions and voting.
Corporate governance
An independent Inspector of Election was appointed to oversee and tabulate voting results.
Quorum was established with 6,746,169 shares represented out of 9,598,201 entitled to vote.
Board and executive committee updates
Three nominees for Class II directors were presented for election to serve three-year terms.
No stockholder nominations for directors were received; nominations were closed.
Latest events from Adicet Bio
- Major mid-year data update for prula-cel in autoimmune diseases and new solid tumor program advancing.ACET
Jefferies Global Healthcare Conference 20264 Jun 2026 - Net loss narrowed, cash runway extends into H2 2027 as pivotal trials advance and risks persist.ACET
Q1 202613 May 2026 - Prula-cel delivers durable remission and immune reset in autoimmune disease, while ADI-212 advances for mCRPC.ACET
Investor presentation13 May 2026 - Vote on directors, executive pay, and auditor ratification at the June 2026 annual meeting.ACET
Proxy filing29 Apr 2026 - Virtual annual meeting to elect directors, approve pay, and ratify auditor, with robust governance.ACET
Proxy filing29 Apr 2026 - Prula-cel delivers steroid-free remissions and immune reset in autoimmune disease patients.ACET
Investor presentation12 Mar 2026 - Biotech seeks up to $250M for cell therapy pipeline, targeting autoimmune and cancer markets.ACET
Registration Filing12 Mar 2026 - Clinical pipeline advances and solid cash position support continued execution into 2027.ACET
Q4 202512 Mar 2026 - Allogeneic Gamma-delta CAR-T therapies advance in autoimmune trials, with initial data imminent.ACET
Canaccord Genuity’s 45th Annual Growth Conference3 Feb 2026